VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2021 | Future research directions for breast cancer

Giuseppe Curigliano, MD, PhD, University of Milan and European Institute of Oncology, Milan, Italy, discusses what he thinks are the most important trials and future research directions in ER-positive, HER2-positive, and triple-negative breast cancer. Oral selective estrogen receptor degraders (SERDs) were an exciting topic at SABCS 2021, with promising data being presented. Dr Curigliano also discusses the NATALEE (NCT03701334) and DESTINY-Breast06 (NCT04494425) trials. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Disclosures

Consultation fees from Pfizer, Roche, Astra Zeneca, BMS, Daichii Sankyo, Seagen, Gilead, Novartis, Lilly; Ellipsis, Merck

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter